Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Med Sci Monit ; 18(8): CR512-517, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22847201

RESUMEN

BACKGROUND: CYP2C9*3 allele has been reported to correlate with increased plasma concentration of fluvastatin active form in healthy volunteers. We analyzed the correlation between the CYP2C9 genotype and cholesterol-lowering effect of fluvastatin in human hypercholesterolemic patients. MATERIAL/METHODS: The study was prospective, without any interventions to standard procedures of hypolipidemic treatment. CYP2C9 genotype was determined by PCR-RFLP assay in 87 patients on concomitant fluvastatin therapy, in 48 patients on monotherapy, and in a control group of 254 healthy volunteers of Czech nationality. Biochemical and clinical data were collected before the initiation of fluvastatin treatment and 12 weeks later. RESULTS: The frequency of CYP2C9 alleles did not differ significantly among groups of patients and volunteers. The most frequently observed allele was CYP2C9*2. Treatment with 80 mg of fluvastatin daily of 48 patients on monotherapy for 12 weeks resulted in mean low-density lipoprotein cholesterol (LDL-C) reduction by 25%, mean serum total cholesterol (TC) reduction by 21%, and mean triglyceride (TG) reduction by 28%. The CYP2C9*1/*3 genotype was associated with a decrease in LDL-C levels (by 40.0% for CYP2C9*1/*3, but only by 22.4% for CYP2C9*1/*1), and with the reduction of TC (by 28.6% in CYP2C9*1/*3 versus 20.2% in CYP2C9*1/*1). CONCLUSIONS: In hypercholesterolemic patients, LDL-C serum concentration was decreased more significantly in fluvastatin-treated subjects bearing the CYP2C9*1/*3 genotype compared to CYP2C9*1/*1 genotype. However, due to rare occurrence of some CYP genotypes, it was impossible to report a definitive positive genotype-fluvastatin effect association.


Asunto(s)
Anticolesterolemiantes/farmacología , Hidrocarburo de Aril Hidroxilasas/genética , Ácidos Grasos Monoinsaturados/farmacología , Frecuencia de los Genes/genética , Indoles/farmacología , Polimorfismo de Nucleótido Simple/genética , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Anticolesterolemiantes/efectos adversos , Estudios de Casos y Controles , Colesterol/sangre , Citocromo P-450 CYP2C9 , Checoslovaquia , Demografía , Ácidos Grasos Monoinsaturados/efectos adversos , Femenino , Fluvastatina , Genotipo , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/tratamiento farmacológico , Hipercolesterolemia/genética , Indoles/efectos adversos , Masculino , Persona de Mediana Edad , Prevalencia
2.
Genet Test Mol Biomarkers ; 16(7): 812-6, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22313047

RESUMEN

AIM: CYP2C8 represents 7% of the hepatic cytochrome system and metabolizes around 5% of drugs in phase I processes. It also plays a significant role in metabolism of endogenous compounds. More than 20 single-nucleotide polymorphisms (SNPs) have been noted, mainly in exons 3, 5, and 8. The most studied SNPs may lead to decreased enzyme activity and may have impact on drug metabolism. Variant alleles are called CYP2C8*2 (I269F), CYP2C8*3 (R139K, K399R), and CYP2C8*4(I264M). Our aim was to investigate the frequency of major functional SNPs among the Czech population. MATERIAL AND METHODS: DNA was isolated from whole blood of 161 healthy, young, and unrelated subjects (94 men and 67 women, aged from 23 to 28 years). The genotypes of polymorphic positions CYP2C8*2, CYP2C8*3 (G416A, A1196G), and CYP2C8*4 were determined by polymerase chain reaction-restriction fragment length polymorphism. RESULTS AND CONCLUSION: Observed allele frequencies were 10.9%, 5.9%, and 0.3% for the alleles CYP2C8*3, CYP2C8*4, and CYP2C8*2, respectively. Both CYP2C8*3 (G416A, A1196G) alleles have been found in complete linkage disequilibrium. The allele distribution complies well with Hardy-Weinberg equilibrium. Allele frequencies of functionally important CYP2C8 variants in the Czech population are similar to that of other Caucasian populations.


Asunto(s)
Alelos , Hidrocarburo de Aril Hidroxilasas/genética , Frecuencia de los Genes , Polimorfismo de Longitud del Fragmento de Restricción , Polimorfismo de Nucleótido Simple , Adulto , Hidrocarburo de Aril Hidroxilasas/metabolismo , Citocromo P-450 CYP2C8 , República Checa , Exones/genética , Femenino , Humanos , Masculino
3.
Nucleosides Nucleotides Nucleic Acids ; 27(6): 835-8, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18600549

RESUMEN

Genetic variation in thiopurine S-methyltransferase (TPMT) is a major factors for wide variation in the metabolism and safety of thiopurine drugs. We investigated the frequency of functional gene polymorphisms in 396 patients with inflammatory bowel disease and 300 healthy subjects. Frequencies of functionally deficient alleles TPMT*2, TPMT*3A, TPMT*3B, and TPMT*3B in the patient group were 0.1%, 4.3%, 0.1%, and 0.4%, respectively, and were similar to those of healthy subjects in the Czech population. Our results provide necessary information for pharmacoeconomic studies in the Czech Republic.


Asunto(s)
Salud , Enfermedades Inflamatorias del Intestino/enzimología , Enfermedades Inflamatorias del Intestino/genética , Metiltransferasas/genética , Polimorfismo Genético/genética , Azatioprina/uso terapéutico , Estudios de Casos y Controles , República Checa , Frecuencia de los Genes , Genotipo , Humanos , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico
4.
Cell Biochem Funct ; 26(1): 76-81, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-17311358

RESUMEN

CYP2D6 is a member of cytochrome P450 enzymes that metabolise over 25% of commonly used drugs. Genetic polymorphisms can cause insufficient drug efficacy at usually administered doses or can be the cause of adverse drug reaction. CYP2D6 genotyping can be used to predict CYP2D6 phenotype and thereby explain some abnormalities in drug response and thus optimize pharmacotherapy. The aim of this study was to investigate the frequency of functionally important variant alleles of the CYP2D6 gene throughout the Czech population to predict the prevalence of ultra-rapid and poor metabolizer phenotypes. The DNA of 223 unrelated, healthy volunteers was analysed to detect the presence of CYP2D6*6, *5, *4, *3 and gene duplication. The variant allele frequencies in our population were 0.22%, 3.14%, 22.87%, 1.12% and 3.14% for CYP2D6*6, CYP2D6*5, CYP2D6*4, CYP2D6*3 and CYP2D6*MxN, respectively. Fifteen subjects carried two variant alleles leading to predicted poor type of metabolism, 84 subjects were heterozygous extensive metabolizers (het-EM). The full-text contains detailed comparison with European white populations. The distribution of variant alleles complies with the Hardy-Weinberg equilibrium. The frequencies of functional variant alleles of CYP2D6 in Czech population are in concordance with other Caucasian populations.


Asunto(s)
Citocromo P-450 CYP2D6/genética , Frecuencia de los Genes , Polimorfismo de Nucleótido Simple , Adolescente , Adulto , Anciano , Citocromo P-450 CYP2D6/fisiología , República Checa , Femenino , Genética de Población , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Preparaciones Farmacéuticas/metabolismo , Farmacogenética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA